Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2023
2022
2022
2021
Profitability Metrics
Gross Margin
34.92%
Operating Margin
10.24%
Net Margin
8.06%
Efficiency Metrics
Revenue per Expense Ratio
1.11
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
13.27%
Income Tax Rate
20.61%
EPS
12.7200000000
Balance Sheet Analysis
Current Ratio
1.78
Cash Ratio
0.65
Working Capital
$2.14B
Debt to Equity
1.63
Debt to Assets
45.79%
Equity Ratio
28.11%
Cash Flow Analysis
Operating Cash Flow Ratio
11.76%
Free Cash Flow Ratio
7.24%
CapEx to Revenue
4.52%
Dividends Paid
$351.20M
Stock Buybacks
$747.47M
Total Shareholder Returns
$1.10B
Cash Position Change
-6.40%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased dividend payments by 103.24%
Detailed Growth Metrics
Core Performance
Revenue
4.98%
Net Income
0.32%
EPS
-5.29%
Operating Income
-12.35%
Operational Efficiency
R&D Expenses
0.00%
SG&A Expenses
14.21%
Operating Cash Flow
65.68%
Free Cash Flow
68.50%
Balance Sheet Health
Assets
3.55%
Debt
1.40%
Book Value per Share
-2.16%
Inventory
0.63%
Shareholder Returns
Dividends per Share
103.24%
Shares Outstanding
5.96%
Long Term Trends
3Y Revenue/Share
38.70%
5Y Revenue/Share
82.78%
3Y Dividend/Share
234.76%
5Y Dividend/Share
367.21%